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Toll-like receptors (TLRs), a family of pattern recognition receptors expressed on many 
cell types of innate immunity, recognize the pathogen-associated molecular patterns 
of microbes. The hygiene hypothesis suggests that a reduced microbial exposure 
in early childhood increases the susceptibility to allergic diseases due to deviation 
in development of the immune system. TLRs are key roles in the right and healthy 
direction of adaptive immunity with the induction of T-helper 2 toward Th1 immune 
responses and regulatory T cells. TLR ligand CpG-ODN-based immunomodulation 
is independent of allergen and it mainly affects innate immune system. While, 
CpG-oligodeoxynucleotide-based vaccination is allergen specific and induces 
adaptive immune system. The use of agonists of TLR9 in two distinct strategies of 
immunotherapy, immunomodulation and vaccination, could be presented as the 
curative method for the treatment of allergic diseases.
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The incidence of allergic diseases is increas-
ing globally and has reached a point to be a 
costly public health issue, especially in indus-
trialized countries [1]. The probable expla-
nation is the ‘hygiene hypothesis’, which 
implies an inverse relationship between 
increasing allergic diseases and the lack of 
exposure to microbes during early child-
hood [2]. Therefore, allergens play the major 
role in creating allergic diseases and inhaled 
or food allergens could cause severe reactions 
such as anaphylactic shock in some people [3]. 
The immunopathology of these diseases 
result from T helper 2 (Th2) cells immune 
responses against harmless environmental 
antigens. The main role of Th2 cells is to 
produce IL-4 and IL-5, which can develop 
allergic reactions [4]. Also, IL-4 promotes 
differentiation of naive TH0 cells to TH2 
phenotype and stimulates B cells to secrete 
IgE. Additionally, IL-5 increases the develop-
ment of eosinophils from progenitor cells [5]. 
In allergic diseases in addition to the increase 
in Th2 activity, Th1 cell type cytokine secre-
tion will be ameliorated [6]. It has been shown 
that exposure to bacterial and viral infections 
in childhood would enhance the immune 
system toward Th1 cells [7]. Therefore, the 
increasing incidence of allergic diseases could 
be associated with the decrease in infections 
during childhood.
Toll-like receptors (TLRs) play an essen-
tial role in the early innate immune response 
against microbial pathogens [8,6]. TLRs 
express on the surface or in the vacuoles of 
cell subsets which are involved in the host 
defense such as neutrophils, natural killer 
cells (NKCs) and antigen-presenting cells 
(APCs). Different component of pathogens 
inducing TLR signaling are called pathogen-
associated molecular patterns. Also, TLRs 
trigger dendritic cells (DCs) maturation 
which induces the expression of costimula-
tory molecules and secretion of i nflammatory 
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cytokine such as TNF-α, IL-1, IL-6 and IL-12. These 
cytokines induce Th1 immune responses and prevent 
differentiation of Th2 cells [7]. Additionally, it has been 
known that TLRs express on regulatory T cells, which 
then play an important role in the modulation of 
immune system [7]. In conclusion, it has been proposed 
that TLRs play an important role in reducing Th2-
mediated allergic responses and prevent the develop-
ment of allergic diseases [7]. It is suggested that TLRs 
can be used for the treatment of allergic diseases.
Toll-like receptors
TLRs are highly conserved pattern recognition recep-
tors in vertebrates and insects and play a significant 
role in activation of the innate immune system. A 
class of type I transmembrane proteins were identi-
fied in Drosophila, which are important in defense 
against infection [9,10]. The members of TLRs have 
two important domains; the extracellular which con-
sists a leucine-rich region, and has an important role 
in binding to the ligands and the intracellular domain 
with approximately 200 amino acids. The similarity of 
this latter region with IL-1 receptor called Toll/IL-1R 
(TIR) domain makes it necessary for the downstream 
signaling. These receptors are expressed mainly on 
macrophages and DCs which recognize specific micro-
bial structures called pathogen-associated molecular 
patterns [11,12]. The TLRs including TLR1, 2, 4, 5, 6 
and 11 are expressed on the surface of cells and TLR3, 
7, 8 and 9 which recognize nucleic acid are expressed 
in the cells [13].
TLRs recognize specific ligands that form a part of 
components of microbial pathogens as part of com-
ponent of microbial pathogens. Signal transduction 
happens by these receptors which lead to activation of 
adaptor proteins and the transcription factors includ-
ing NF-κB and activator protein (AP)-1. These fac-
tors trigger inflammatory responses and interferon 
regulatory factor (IRFs), which finally create antiviral 
responses leading to eradication of pathogens [14]. The 
heterodimers TLR1/TLR2 and TLR2/TLR6 recognize 
various bacterial components including peptidoglycan, 
lipoproteins and lipoarabinomannan of mycobacteria 
and zymosan of yeast [14–17]. Moreover, TLR3, TLR8 
and TLR9 express the intracellular vacuoles that detect 
dsRNA, ssRNA of many viruses and bacterial unmeth-
ylated CPG DNA, respectively [14,18,19,20,21,22]. Also, 
lipopolysacaride of Gram-negative bacteria and lipoti-
choic acids of Gram-positive bacteria are recognized by 
TLR4 and TLR5 recognizes bacterial flagellin [23].
TLRs utilize different adapter proteins such as 
MyD88, TIR-associated protein (TIRAP), MyD88 
adaptor-like protein, TIR domain-containing adap-
tor protein-inducing IFN-β (TRIF) and TRIF-related 
adaptor molecule. All the TLRs utilize MyD88 as 
an adaptor protein in their signaling pathway except 
TLR3 which utilizes TRIF. TRIF-related adaptor mol-
ecule and TIR-associated protein are adaptor p roteins 
that are used by TLR4 [14].
According to the research conducted in the field of 
molecular immunology, TLRs are as novel targets in 
the prevention and treatment of allergic diseases [9,24,25]. 
The involvement of TLRs trigger a cascade of cell 
signaling that leads to the production of Th1-related 
cytokines such as IL-12 and IFN-γ. These cytokines 
modulate allergic responses by prevention of IL-4 and 
IL-5, which are secreted by Th2 lymphocytes [26]. In 
this review the method of TLR9 immunotherapy in 
the treatment of allergic diseases will be discussed.
Natural & synthetic ligands of TLR9
TLR9 is one of the members of the TLRs family 
expressed dominantly in B lymphocytes and plasmacy-
toid DCs (
P
DCs). It is located in the endoplasmic retic-
ulum, endosome and lysosome [27,28]. This glycopro-
tein has an extracellular leucin-rich and cytoplasmic 
signaling domain [29]. TLR9 recognizes unmethylated 
CpG dinucleotides which are common in bacterial and 
viral genomes and relatively rare (∼1%) in vertebrate 
genomes [30]. In prokaryotes DNA, methylation occurs 
rarely and cytosines are unmethylated in comparison 
with vertebrate genomes [30,31]. Not only natural DNA-
derived bacteria and viruses, but also synthetic oligo-
deoxynucleotides (ODN) containing unmethylated 
CpG motifs are ligands for TLR9 [32]. Activation of 
TLR9 by CpG DNA or ODN leads to induction of 
strong Th1 immune response. Th1 produces cytokines 
such as IL-12, IL-18 and IFN-γ, which continues to 
activate the NKC and enhances CD8 T-cell response. 
Finally, these activities of Th1 inhibit Th2-type 
immune response and cytokines production of IL-4 
and IL-5 [33].
CpG-ODNs are also called immunostimulatory 
sequence-ODN (ISS-ODN) [26]. ISS-ODNs contain 
unmethylated CpG dinucleotides within a palindromic 
hexamer having the formula: 5′-purin-purin-CpG-
pyrimidin-pyrimidin-3′ [34]. There are five classes of 
CpG-ODNs based on their sequence, secondary struc-
tures and effect on human peripheral blood mononu-
clear cells (PBMCs) which contain classes of A (Type 
D), B (Type K), C, P and S [32,35,36].
Class A has potential for inducing IFN-α produc-
tion by 
p
DC. Its backbone structure is mainly a phos-
phodiester with a phosphorothioate at one or both ends 
of ODN [37,38]. Class B strongly activates B cells pro-
liferation and production of antibody [30]. Class C has 
the mechanism of action similar to class A and B [39,40]. 
Phosphorothioate-ODN mainly activates B cell and up 
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to less extent activates macrophages or NKCs. On the 
contrary, phosphodiester-ODN is a potent activator for 
macrophages or NKCs rather than B-cell proliferation 
(Table 1) [30].
TLR9 signaling
TLR9 signaling consists of two distinct pathways: the 
myD88-dependent and myD88-independent path-
ways [41]. Stimulation of TLRs by their ligands leads 
to the activation of transcription factor such as AP-1, 
NF-κB and IRFs [41]. The myD88-dependent path-
way leads to the production of inflammatory cyto-
kines such as IL-6, IL-12P40 and TNF while the 
myD88-independent pathway mediates type I IFN 
response [41]. Binding of TLR9 to its ligand leads to 
conformational changes in cytoplasmic TIR domain 
resulting in the recruitment of adaptor proteins includ-
ing myD88 which is essential for initiating TLR9 
signaling [35]. Upon recruitment of myD88 to TIR 
domain, it interacts with interleukin-receptor asso-
ciated kinase-4 (IRAK4), and subsequently causes 
phosphorylation of IRAK4 which leads to activation 
of IRAK1 [42,41]. After the separation of IRAK1 and 
IRAK4 from myD88-TLR complex, they activate 
TNF receptor associated factor (TRAF-6) [41]. Activa-
tion of TRAF-6 leads to the activation of TGF-β acti-
vated kinase 1 (TAK1) and TAK1-binding proteins 
(Tables 1 & 2). TAK1 activates the IκB kinase (IKK) 
complex (IKKα, IKKβ and NEMO/IKKγ). IKK com-
plex phosphorylates IKB which subsequently activates 
NF-κB, inducing production of inflammatory cyto-
kines such as TNF, IL-1 and IL-12 [43]. Moreover, 
IRAK1 phosphorylates and activates IRF7 causing the 
induction of type I IFNs which are essential for the 
defense against viral infections (Figure 1) [43,44].
CpG-immunonomadulation versus 
vaccination
CpG (ISS)-ODN induces Th1-based immune response 
and produces IFN-γ and IgG2a which prevents the 
development of Th2-mediated hypersensitivity in 
mouse models of allergic diseases [34,45]. T herefore, 
ISS-ODNs could be effective in the treatment of aller-
gic diseases [35]. There are two distinct strategies for the 
use of ISS-ODN in the treatment of allergic diseases: 
immunomodulation and vaccination [34]. ISS-ODN 
based immunomodulation is independent of allergen 
and it mainly affects innate immune system leading 
to the activation of NKC, MQ and DC. The thera-
peutic effects of ISS-ODN based immunomodulation 
develop rapidly and persist for a short term (for weeks). 
While, ISS-ODN based vaccination is allergen specific 
and induces adaptive immune system. Its effects in the 
treatment of allergic diseases develop slowly with long-
term duration that remains for at least 1 year [34,46]. 
Consequently, both the ISS-ODN based immuno-
modulation and vaccination are effective in the treat-
ment of allergic diseases.
Moreover, studies have shown that ISS-ODN based 
vaccination can prevent the immediate hypersensitiv-
ity response and late-phase allergic reaction [45]. Vac-
cination with ISS-ODN was done in two different 
strategies: ISS-ODN mixed and conjugated allergens 
(AIC) [46]. Both the methods shift Th2 toward Th1 
immune response, which then leads to the treatment of 
allergic diseases [46]. However, studies have shown that 
AIC improves immunogenicity and reduces allerge-
nicity in comparison with mixed allergens [46,47]. Due 
to colocalization of ISS-ODN and allergen on APCs, 
uptake and presentation of allergen by APCs will be 
facilitated and leads to increase immunogenicity with 
AIC [48]. Conjugation of allergen to ISS-ODN masks 
allergen epitopes thereby, prevents recognition of epit-
opes by specific IgE which finally leads to reduction in 
allergenicity by AIC [39]. In addition, AIC induces Th1-
based immune responses such as IFN-γ and IgG2a. 
Also, it reduces IL-5 response compared with aller-
gen mixed ISS-ODN, significantly (Tables 2 & 3 and 
Figure 2) [34,45].
Immunotherapy based CpG-ODN leads to induc-
tion of Th1, regulatory T lymphocytes response and 
activation of innate immune system which reduces 
Th2 response [26]. Therefore, binding of CpG-ODN 
to TLR9 produces IL-12 and IL-10 by DCs leading to 
Table 1. Comparison of the effects of the different classes of CpG-CpG-oligodeoxynucleotide.
ODN classes IFN-α secretion B-cell proliferation PDC maturation
A-ODN +++ + ++
B-ODN + +++ +++
C-ODN ++ +++ +++
P-ODN ++ + +++
S-ODN - - -
+: week effect, ++: moderate effect, +++: strong effect.
ODN: Oligodeoxynucleotide; pDC: Plasmacytoid dendritic cell.
Data taken with permission from [37].
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the induction of Th1 and regulatory T lymphocytes 
responses [49].
It has been shown that CpG-ODN induces the pro-
duction of indoleamine 2,3-dioxygenase by DCs [26,50]. 
This enzyme enhances the number and function of 
T-regulatory lymphocytes [52]. Therefore, immuno-
therapy with CpG-ODN induces T-regulatory cells 
and indoleamine 2,3-dioxygenase leading to the sup-
pression of Th2 responses and so clinical manifestation 
of allergic diseases [49,51]. Based on the above informa-
tion, CpG-ODN immunotherapy could be used in the 
treatment of allergic diseases.
CpG-ODN immunotherapy in animal models
Allergic rhinitis
Different studies have shown the potentials of CpG-
ODN immunotherapy in the treatment of allergic rhi-
nitis in animal models [52,53]. Hussain et al. showed that 
CpG-ODN immunotherapy in mice model of allergic 
rhinitis sensitized with OVA markedly decreased nasal 
irritation and eosinophil count in their airways [52]. Also, 
Rhee et al. showed that treated mice with CpG-ODN 
decreased release of histamine and nasal e osinophilic 
inflammation [53]. Moreover, immune responses of the 
mice shifted from Th2 toward Th1 cells. In the same 
investigation they showed that the efficacy of CpG-
ODN in reducing allergic i nflammation was more 
than dexamethasone [53].
Asthma
Based on studies conducted on murine models of 
asthma, it has been shown that CpG-ODN immu-
notherapy could reduce Th2-based responses leading 
to improvement in manifestation of asthma [54–56]. 
Kline et al. reported that CpG-ODN immunotherapy 
in C57BL/6 model of asthma which was sensitized to 
soluble egg antigen from the schistosome, decreased 
eosinophilia and bronchial airway infiltration of aller-
gic inflammatory cells [54]. CpG-ODN immunother-
apy also increased Th1 cytokines such as IL-12 and 
IFN-γ and attenuated manifestations of asthma in 
C57BL/6 model [54].
The results from another study showed that ISS-
ODN immunotherapy in ragweed sensitized mice 
inhibited production of Th2 cytokines and suppressed 
the rise in specific IgE after allergen challenge [55]. 
Also, Santeliz et al. reported that administration of 
CpG-ODN in murine model of asthma induced Th1 
immune response. Additionally, they showed that 
CpG-ODN conjugated allergen was more effective 
than CpG-ODN mixed with allergen in attenuation 
of Th2-driven allergic airway responses [56]. Moreover, 
it has been shown that administration of AIC in mice 
model of asthma induced IFN-γ and decreased IL-4 
and IL-5 [57].
Other allergic disorders
CpG-ODN immunotherapy has been investigated 
as a new therapeutic method for the treatment of 
other allergic disorders such as conjunctivitis, airway 
remodeling and anaphylactic shock. In murine model 
of allergic conjunctivitis induced by ragweed, CpG-
ODN immunotherapy considerably reduced the level 
of ragweed-specific IgE and late-phase infiltration 
of allergic cells [58]. Also, Cho et al. investigated the 
effects of CpG-ODN on the airway remodeling. They 
Table 2. Properties of immunostimulatory sequence-oligodeoxynucleotide-based 
immunomodulation versus vaccination.
 Immunomodulation Vaccination
Targeting Innate immunity Adaptive immunity
Effects duration Short-term (weeks) Long-term (months/years)
Type of cell type effects NK, MQ, DC B cell, Th1
Cytokine induction IFN-α /β/γ, IL-12, IL-6, IL-18, ↓ IL-4 receptor IFN-γ, IL-10, IL-4, ↓ IL-5, IL-13
DC: Dendritic cell; MQ: Macrophage; NK: Natural killer; Th1: T-helper 1.
Figure 1. Schematic Toll-like receptor 9 signaling pathway.
TLR9
IRAK1 IRAK4
TRAF6
TRAF3
IRF7 AP-1
MAPKs
TAK1
MyD88
NEMO/IKKγ
IKKαIKKβ
IKB
NF-κB
NF-κB
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found that CpG-ODN immunotherapy in sensitized 
mice with allergen reduced the level of TGF-β as a pro-
fibrotic cytokine. Peribronchial fibrosis and mucous 
production was inhibited in these mice. Therefore, 
immunotherapy with CpG-ODN inhibits TGF-β 
production and airway remodeling [59]. Similarly, 
Fanuchi and colleagues have reported that CpG-ODN 
immunotherapy reduced eosinophilic inflammation 
and prevented airway remodeling in a model of allergic 
monkey [60].
Importantly, it was found that administration of 
OVA conjugated CpG-ODN in mice model of ana-
phylactic shock, increased Th1 dominant immune 
response which causes a decrease in IgE level and pro-
tected OVA sensitized BALB/c mice from anaphylactic 
shock [61].
CpG-ODN immunotherapy in human clinical 
trials
Allergic rhinitis
Results of an investigation by Creticos et al. showed 
that immunotherapy using conjugated ISS-ODN 
and Amb a1 (AIC) in adults with allergic rhinitis 
(AR) reduced acute allergic responses. Also, AIC 
increased Amb a1 specific IgG but reduced the Amb 
a1 specific IgE. Therefore, they suggested that AIC 
immunotherapy could be used for the treatment of 
ragweed AR [62]. In another study by Asai et al. it 
was found that immunotherapy with AIC in sub-
jects with AR after seasonal ragweed-pollen expo-
sure increased CD4+CD25+ T regulatory cell in the 
nasal mucosa [63]. Our previous study was performed 
to investigate the effect of CpG-ODN in alteration 
of T-helper (Th)1/Th2 balance of patients with AR 
treated with intranasal corticosteroids and antihis-
tamines. PBMCs of patients with AR were isolated 
before and after 45 days therapy. Cytokine production 
and specific Ch.a IgE in response to CpG co-admin-
istration of natural chenopodium album (CpG/Ch.a) 
or recombinant Ch.a (CpG/rCh.a) allergen were 
investigated in supernatants of cultured PBMCs using 
ELISA. Intra cellular IL-10 was also assessed in CD4+ 
cells using flow cytometry. The results of our study 
showed that treatment of PBMCs of patients with 
 chenopodium album AR by CpG ODN mixed aller-
gen induced IFN-γ and IL-10 while suppressed IL-4 
and IL-13 [64]. Moreover, Tulic et al. investigated the 
effect of AIC in ragweed-sensitive patients with AR. 
They examined the role of AIC on eosinophilia and 
cytokine mRNA expression in the nasal mucosa of 
the two groups (AIC and placebo-treated patients). 
The results of the above study showed that after 4 to 5 
months AIC immunotherapy, eosinophilia and IL-4 
mRNA-positive cells were significantly decreased. 
Additionally, the number of IFN-γ mRNA-positive 
cells was increased in AIC-treated patients as com-
pared with the placebo. Also, the allergic symptoms 
of AIC-treated patients were decreased [65].
Asthma
It has been shown that A-type of CpG- ODN in virus-like 
particles package was effective in reducing symptoms of 
AR and asthma [66]. Also, Gauvreau et al. reported that 
immunotherapy with ISS-ODN in subjects with aller-
gic asthma, significantly increased expression of IFN-γ, 
monokine induced by IFN-γ (MIG), IFN-stimulated 
gene (ISG)-54, monocyte chemotactic protein (MCP)-1 
and MCP-2 [67]. Also, the treatment of patients with 
Table 3. The effects of three methods immunotherapy on the production of some cytokines.
Immunotherapy by IFN-γ IgG2a IL-5
Allergen only + + +++
Allergen–ISS conjugate +++ +++ +++
Allergen–ISS mix ++ ++  
+: week effect, ++: moderate effect, +++: strong effect.
ISS: Immunostimulatory sequence.
Figure 2. Co-administration of CpG and allergen induces Th1 and 
regulatory T and B cells, which inhibit Th2 cells. 
APC: Antigen-presenting cell; Th: Helper T cell; T reg: Regulatory T cell.
APC
Th1
Allergen + CpG
IL-10Th0 Treg
B cell
IL-12, IFN-γ
IL-6
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allergic asthma by QbG10 was found to be effective in 
the control of asthma. QbG10 is a novel TLR9 agonist 
packaged into virus-like particles that stimulates the 
immune system toward a Th1 immune response [68]. 
Additionally, immunotherapy with a house dust mite 
allergen extract along with A-type CpG ODN packaged 
into virus-like particles (QbG10) reduced symptoms of 
AR and asthma [66].
Other allergic disorders
With regard to CpG-ODN immunotherapy used in 
the treatment of other allergic disorders, the report 
from an investigation on human patients with rag-
weed allergy showed that ISS-ODN conjugated Amb 
a1 expressed Th1 cytokine while down regulated Th2 
cytokine in PBMCs [69]. Also, Tulic et al. demonstrated 
that AIC immunotherapy was effective in inhibition of 
allergen specific Th2 and induction of allergen specific 
Th1 responses in ragweed allergic subjects [70]. More-
over, in another study it was shown that AIC immuno-
therapy was a potent agent for inducing Th1 immune 
responses in patients with ragweed allergy [71].
In another study, Klimek et al. used nanoparticles 
which were loaded with TLR9 ligands (CYT003-
QbG10) in patients with rhinoconjunctivitis. They 
found that Rhinoconjunctivitis symptoms were 
s ignificantly lower in patients treated with high 
dose CYT003-QbG10 as compared with the pla-
cebo. Therefore, treatment with CYT003-QbG10 
was found to be safe and tolerable in patients suf-
fering from allergy [72]. Also, it was shown that AIC 
immuno therapy in patients with ragweed allergy 
caused redirection of immune response toward Th1 
and significantly increased IFN-γ, CXCL9, CXCL10 
while decreased IL-5, CCL17 and CCL22 [73].
Future perspective
Immunotherapy with CpG-ODN could be applied by 
two distinct strategies: immunomodulation and vacci-
nation. Therefore, these data suggest that CpG-ODN 
immunotherapy could be a novel therapeutic method 
for the treatment of asthma and allergic diseases.
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Executive summary
•	 CpG-oligodeoxynucleotide (ODN) was used as an adjuvant for the treatment of asthma and allergic diseases in 
mice models and humans.
•	 Immunotherapy with CpG-ODN could be applied by two distinct strategies: immunomodulation and 
vaccination.
•	 CpG-ODN vaccination is allergen specific and has a long lasting effect on immune system rather than 
immunomodulation. Both methods are effective in the prevention and treatment of allergic disease in murine 
models and clinical trials.
•	 Immunotherapy with CpG-ODN decreases eosinophilic inflammation, Th2 responses, IgE levels and Th2 
cytokines expression including IL-4 and IL-5. On the contrary, it increases Th1 cell responses, cytokine secretion 
of IFN-γ, IL-6, IL-12 and induces regulatory T cells. Moreover, CpG-ODN immunotherapy by induction of 
indoleamine 2,3-dioxygenase suppresses Th2-mediated responses in the murine models of allergic diseases.
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